Cited by 293Renin-Angiotensin System StudiesBlood Pressure and Hypertension StudiesChronic Kidney Disease and Diabetes

The DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index.

Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes

Jandeleit-Dahm, Karin AM, Tikellis, Christos, Reid, Christopher M, Johnston, Colin I, Cooper, Mark E·2005·Journal of Hypertension

DOI 10.1097/01.hjh.0000160198.05416.72

Open this paper in CoChat — free account

Abstract

Recent trials have suggested that inhibitors of the renin-angiotensin system (RAS), such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), may reduce the incidence of new-onset diabetes in patients with or without hypertension and at high risk of developing diabetes. In this review, we critically evaluate the evidence from recent clinical trials for such a potential preventive effect of ACE inhibitors and ARBs, including a meta-analysis of these recent trials. The reduced incidence of diabetes in patients at high risk of developing diabetes by ACE inhibitors or ARBs has been explained by haemodynamic effects, such as improved delivery of insulin and glucose to the peripheral skeletal muscle, and non-haemodynamic effects, including direct effects on glucose transport and insulin signalling pathways, all of which decrease insulin resistance. There is now evidence that the pancreas may contain an in situ active RAS, which appears to be upregulated in an animal model of type 2 diabetes. Thus, ACE inhibitors and ARBs may act by attenuating the deleterious effect of angiotensin II on vasoconstriction, fibrosis, inflammation, apoptosis and beta-cell death in the pancreas, thereby protecting a critical beta-cell mass essential for insulin production. New evidence is presented that ACE inhibitors and ARBs may delay or prevent the development of insulin resistance and diabetes, for which novel mechanisms are suggested. The actions of agents that interrupt the RAS on insulin resistance, obesity and diabetes warrant further investigation in other animal models. Prospective clinical studies with the primary endpoint of the prevention of diabetes are now indicated to (i) further explore whether the inhibitors of the RAS are superior compared to other antihypertensive agents such as calcium channel blockers (CCBs) and (ii) to evaluate the potential beneficial effects of combination antihypertensive regimens on the development of diabetes.

Integrity signals

Registry

Crossref · 10.1097/01.hjh.0000160198.05416.72

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease
DeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,555
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy
(2000) · The Lancet · doi:10.1016/s0140-6736(99)12323-7 · Cited by 3,179
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
(2001) · The Lancet · doi:10.1016/s0140-6736(01)06178-5 · Cited by 3,178
Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.
Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., & Alexander, R. W. (1994) · Circulation Research · doi:10.1161/01.res.74.6.1141 · Cited by 2,735
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14286-9 · Cited by 2,142
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Hansson, L., Lindholm, L. H., NISKANEN, L. K., Lanke, J., Hedner, T., Niklason, A., LUOMANMÄKI, K., Dahlöf, B., Fairé, U. D., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 1,991

Show all 89 references

Research works printed but not linked: 3

2000, Heart Outcomes Prevention Evaluation Study Investigators., Lancet, 355, 253
1999, National Intervention Cooperative Study in Elderly Hypertensives Study Group., Hypertension, 34, 1129
1997, Diabetes C, are, 20, 1183

Sorted by citations

Items 101–200 of 292

Does interference with the renin–angiotensin system protect against diabetes? Evidence and mechanisms
van der Zijl, N. J., Moors, C. C. M., Goossens, G. H., Blaak, E. E., & Diamant, M. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01559.x · Cited by 36
Angiotensin-(1-7) Participates in Enhanced Skeletal Muscle Insulin Sensitivity After a Bout of Exercise
Echeverría‐Rodríguez, O., Gallardo‐Ortíz, I. A., del Valle‐Mondragón, L., & Villalobos‐Molina, R. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa007 · Cited by 35
Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes
Barzilay, J. I., Gao, P., Rydén, L., Schumacher, H., Probstfield, J. L., Commerford, P., Dans, A., Ferreira, R., Keltai, M., Paolasso, E., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0545 · Cited by 35
Effect of Delapril/Manidipine vs Olmesartan/ Hydrochlorothiazide Combination on Insulin Sensitivity and Fibrinogen in Obese Hypertensive Patients
Fogari, R., Derosa, G., Zoppi, A., Lazzari, P., Corradi, L., Preti, P. S., & Mugellini, A. (2008) · Internal Medicine · doi:10.2169/internalmedicine.47.0449 · Cited by 35
Renin–angiotensin-system blockade in the prevention of diabetes
Östergren, J. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.01.018 · Cited by 34
Prescribing angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease (Review Article)
Ferrari, P. (2007) · Nephrology · doi:10.1111/j.1440-1797.2006.00749.x · Cited by 34
Diabetes Mellitus-Associated Atherosclerosis
Calkin, A. C., & Allen, T. J. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606010-00003 · Cited by 31
Association between risk of type 2 diabetes mellitus and angiotensin-converting enzyme insertion/deletion gene polymorphisms in a Saudi Arabian population
Alsaikhan, F., Abdel-Aziz, M. A., & Ashour, R. H. (2017) · Biomedical Reports · doi:10.3892/br.2017.920 · Cited by 31
Effect of Telmisartan, Angiotensin II Receptor Antagonist, on Metabolic Profile in Fructose-Induced Hypertensive, Hyperinsulinemic, Hyperlipidemic Rats
Kamari, Y., Harari, A., Shaish, A., Peleg, E., Sharabi, Y., Harats, D., & Grossman, E. (2008) · Hypertension Research · doi:10.1291/hypres.31.135 · Cited by 31
Beyond the classic angiotensin-receptor-blocker profile
Kurtz, T. W. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0805 · Cited by 31
Diabetic nephropathy - Epidemiology in Asia and the current state of treatment
Ritz, E., & Zeng, X. (2011) · Indian Journal of Nephrology · doi:10.4103/0971-4065.82122 · Cited by 30
Angiotensin II induces cholesterol accumulation and impairs insulin secretion by regulating ABCA1 in beta cells[S]
Lyu, J., Imachi, H., Fukunaga, K., Sato, S., Ibata, T., Kobayashi, T., Dong, T., Yoshimoto, T., Yonezaki, K., Nagata, H., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m085886 · Cited by 14
Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: A meta-analysis of 59,862 patients
Geng, D.-F., Jin, D., Wu, W., Xu, Y., & Wang, J. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.10.011 · Cited by 31
The Potential Role of Osteopontin and Furin in Worsening Disease Outcomes in COVID-19 Patients with Pre-Existing Diabetes
Adu-Agyeiwaah, Y., Grant, M. B., & Obukhov, A. G. (2020) · Cells · doi:10.3390/cells9112528 · Cited by 29
Signaling Crosstalk Angiotensin II Receptor Subtypes and Insulin
Horiuchi, M., Mogi, M., & Iwai, M. (2006) · Endocrine Journal · doi:10.1507/endocrj.53.1 · Cited by 28
Anti‐diabetic effect of blockade of the renin‐angiotensin system
Ando, K., & Fujita, T. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00526.x · Cited by 27
Clinical Manifestations and Natural History of Diabetic Kidney Disease
Ritz, E. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.10.008 · Cited by 28
Distinct Properties of Telmisartan on Agonistic Activities for Peroxisome Proliferator-Activated Receptor γ among Clinically Used Angiotensin II Receptor Blockers: Drug-Target Interaction Analyses
Kakuta, H., Kurosaki, E., Niimi, T., Gato, K., Kawasaki, Y., Suwa, A., Honbou, K., Yamaguchi, T., Okumura, H., Sanagi, M., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.211722 · Cited by 27
Angiotensin receptor blockers improve insulin signaling and prevent microvascular rarefaction in the skeletal muscle of spontaneously hypertensive rats
Rizzoni, D., Pasini, E., Flati, V., Rodella, L. F., Paiardi, S., Assanelli, D., Ciuceis, C. D., Porteri, E., Boari, G. E. M., Rezzani, R., et al. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e328304b060 · Cited by 27
Association of COVID-19 infection and the risk of new incident diabetes: a systematic review and meta-analysis
Zhou, J., Wang, Y., & Xu, R. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1429848 · Cited by 27
Inhibition of Renin-Angiotensin System: Implications for Diabetes Control and Prevention
Prabhakar, S. S. (2013) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31828298ce · Cited by 25
Effect of Valsartan Addition to Amlodipine on Insulin Sensitivity in Overweight-Obese Hypertensive Patients
Fogari, R., Preti, P. S., Zoppi, A., Mugellini, A., Corradi, L., Lazzari, P., Santoro, T., & Derosa, G. (2008) · Internal Medicine · doi:10.2169/internalmedicine.47.1427 · Cited by 24
Comparison of the Effects of Telmisartan and Olmesartan on Home Blood Pressure, Glocose, and Lipid Profiles in Patients with Hypertension, Chronic Heart Failure, and Metabolic Syndrome
Sasaki, T., Noda, Y., Yasuoka, Y., Irino, H., Abe, H., Adachi, H., HATTORI, S., 北田, 博., Morisawa, D., & Miyatake, K. (2008) · Hypertension Research · doi:10.1291/hypres.31.921 · Cited by 24
Prevention of diabetes in hypertensive patients: Results and implications from the VALUE trial
Zhou, M. S. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4331 · Cited by 27
Review: Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension
Gojanovic, B., Feihl, F., Liaudet, L., & Waeber, B. (2008) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2008.007 · Cited by 24
Effects of Antihypertensives on Glucose Metabolism
Siegel, D., & Swislocki, A. (2007) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2007.0016 · Cited by 23
Angiotensin converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: A meta-analysis of 72,128 patients
Geng, D.-F., Jin, D., Wu, W., Liang, Y.-D., & Wang, J. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.06.125 · Cited by 22
Antihypertensive drugs and incidence of type 2 diabetes: Evidence and implications for clinical practice
Asfaha, S., & Padwal, R. S. (2005) · Current Hypertension Reports · doi:10.1007/s11906-005-0063-7 · Cited by 22
ACE Inhibitors and Angiotensin Receptor Antagonists and the Incidence of New-Onset Diabetes Mellitus
Aguilar, D. A., & Solomon, S. D. (2006) · Drugs · doi:10.2165/00003495-200666090-00001 · Cited by 22
Adipose cell–adrenal interactions: current knowledge and future perspectives
Ronconi, V., Turchi, F., Bujalska, I. J., Giacchetti, G., & Boscaro, M. (2008) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2008.01.004 · Cited by 21
Role of Lipotoxicity and Contribution of the Renin-Angiotensin System in the Development of Polycystic Ovary Syndrome
Connolly, A., Leblanc, S., & Baillargeon, J. (2018) · International Journal of Endocrinology · doi:10.1155/2018/4315413 · Cited by 19
Non-canonical signalling and roles of the vasoactive peptides angiotensins and kinins
Costa-Neto, C. M., Duarte, D. Â., Lima, V. M., Maria, A. G., Munhoz, É. P., Rodríguez-Sarmiento, D. Y., Santos, G. A., de Souza, P. C., & Parreiras‐e‐Silva, L. T. (2014) · Clinical Science · doi:10.1042/cs20130414 · Cited by 20
Deletion of AT2 Receptor Prevents SHP-1–Induced VEGF Inhibition and Improves Blood Flow Reperfusion in Diabetic Ischemic Hindlimb
Paquin-Veillette, J., Lizotte, F., Robillard, S., Béland, R., Breton, M.-A., Guay, A., Despatis, M., & Geraldes, P. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309977 · Cited by 20
Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study
Alrashed, A. A., Khan, T. M., Alhusseini, N. K., Asdaq, S. M. B., Enani, M. A., Alosaimi, B., Alkhani, N., Mohzari, Y. A., Alghalbi, M., Alfahad, W. A., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.03.004 · Cited by 19
Heart Failure and Diabetes Mellitus: Dangerous Liaisons
Lee, H. (2022) · International Journal of Heart Failure · doi:10.36628/ijhf.2022.0022 · Cited by 22
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril
Patel, B. M., & Bhadada, S. V. (2013) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2013.827699 · Cited by 19
Insights into the emerging cardiometabolic prevention and management of diabetes mellitus
Lastra‐González, G., Manrique, C. M., Govindarajan, G., Whaley‐Connell, A. T., & Sowers, J. R. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.13.2209 · Cited by 19
Evidence for benefits of angiotensin receptor blockade beyond blood pressure control
Siragy, H. M. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0050-x · Cited by 19
Effect of short-term ACE inhibitor treatment on peripheral insulin sensitivity in obese insulin-resistant subjects
Goossens, G. H., Blaak, E. E., Schiffers, P. M. H., Saris, W. H. M., & van Baak, M. A. (2006) · Diabetologia · doi:10.1007/s00125-006-0458-2 · Cited by 18
Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives
Bozkurt, Ö., Verschuren, W. M. M., Wijer, B. M. A. V. W.-D., Knol, M. J., de Boer, A., Grobbee, D. E., Geerlings, M. I., Heerdink, E. R., & Klungel, O. H. (2008) · Journal of Human Hypertension · doi:10.1038/jhh.2008.62 · Cited by 18
Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients
Hasvold, L. P., Bodegård, J., Thuresson, M., Stålhammar, J., Hammar, N., Sundström, J., Russell, D., & Kjeldsen, S. E. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2014.43 · Cited by 18
Preventive pharmacotherapy in type 2 diabetes mellitus
Kalra, S., Choudhary, N., Unnikrishnan, A., & Ajish, T. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.91183 · Cited by 18
An overview of candesartan in clinical practice
Khawaja, Z., & Wilcox, C. S. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.90 · Cited by 19
An association between angiotensin II type 2 receptor gene A/C3123 polymorphism and glycemic control marker in a general Japanese population
Kotani, K., Fujiwara, S., Tsuzaki, K., Sano, Y., Matsuoka, Y., Hamada, T., & Sakane, N. (2008) · Molecular Biology Reports · doi:10.1007/s11033-008-9263-y · Cited by 17
Renin-angiotensin system activation in renal adipogenesis
Sui, Y., Zhao, H., Fan, R., Guan, J. Z., He, L., Lee, H. M., Chan, J. C. N., & Tong, P. C. Y. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00445.2009 · Cited by 17
Telmisartan is effective to ameliorate metabolic syndrome in rat model – a preclinical report
Cheng, K., Li, Y., Chang, W., Kuo, F. Y., Chen, Z., & Cheng, J. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s187092 · Cited by 17
Prevention of type 2 diabetes mellitus with angiotensin-converting-enzyme inhibitors
Solski, L., & Longyhore, D. S. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070388 · Cited by 17
Initiation of insulin therapy in elderly patients taking oral antidiabetes drugs
Perez, N., Moisan, J., Sirois, C., Poirier, P., & Grégoire, J. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080547 · Cited by 17
Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex)
on behalf of the CASE-J Ex Study Group, Ogihara, T., Ueshima, K., Nakao, K., Fukiyama, K., Oba, K., Yasuno, S., Fujimoto, A., Sato, T. S., Matsuoka, H., et al. (2011) · Hypertension Research · doi:10.1038/hr.2011.120 · Cited by 17
First-line antihypertensive treatment in patients with pre-diabetes: Rationale, design and baseline results of the ADaPT investigation
Zidek, W., Schrader, J., Lüders, S., Matthaei, S., Hasslacher, C., Hoyer, J. D., Bramlage, P., Sturm, C., & Paar, W. D. (2008) · Cardiovascular Diabetology · doi:10.1186/1475-2840-7-22 · Cited by 16
Genetic polymorphism in ADRB-1 is associated with type 2 diabetes susceptibility in Iranian population
Galavi, H., Noorzehi, N., Saravani, R., Sargazi, S., Mollashahee‐Kohkan, F., & Shahraki, H. (2018) · Gene Reports · doi:10.1016/j.genrep.2018.06.019 · Cited by 16
Diuretics: A modern day treatment option? (Review Article)
Gallagher, M., Perkovic, V., & Chalmers, J. P. (2006) · Nephrology · doi:10.1111/j.1440-1797.2006.00598.x · Cited by 16
Individualization of Antihypertensive Drug Treatment
Mancia, G., & Grassi, G. M. (2013) · Diabetes Care · doi:10.2337/dcs13-2013 · Cited by 16
Hypertension treatment update: Focus on direct renin inhibition
Fitzgerald, M. A. (2011) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2010.00589.x · Cited by 17
Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose
Wohl, P., Krušinová, E., Hill, M., Kratochvílová, S., Zidkova, K., Kopecký, J., Neškudla, T., Pravenec, M., Klementová, M., Vrbíková, J., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0436 · Cited by 16
A Pair of “ACEs”
Hersh, E. V., Wolff, M. S., Moore, P. A., Theken, K. N., & Daniell, H. (2021) · Journal of Dental Research · doi:10.1177/00220345211047510 · Cited by 15
Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine
Weycker, D. A., Edelsberg, J., Vincze, G., Kjeldsen, S. E., Jamerson, K., Khan, Z. M., & Oster, G. (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002159 · Cited by 15
Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan
Francischetti, E. A., Celoria, B. M. J., Francischetti, A., & Genelhu, V. A. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.3.289 · Cited by 15
Antihypertensive therapy, new-onset diabetes, and cardiovascular disease
Basile, J. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02009.x · Cited by 15
Functional and Partial Morphological Regression of Established Renal Injury in the Obese Zucker Rat by Blockade of the Renin-Angiotensin System
Šebeková, K., Lill, M., Boor, P., Heidland, A., & Amann, K. (2008) · American Journal of Nephrology · doi:10.1159/000151771 · Cited by 15
Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems
Ernsberger, P. R., & Koletsky, R. J. (2006) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-006-0080-3 · Cited by 15
Evaluation of Antioxidant Therapeutic Value of ACE Inhibitor as Adjunct Therapy on Type 2 Diabetes Mellitus Patients with Cardiovascular Disease
Elfowiris, A., & Banigesh, A. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00269 · Cited by 14
Elastase-2, a Tissue Alternative Pathway for Angiotensin II Generation, Plays a Role in Circulatory Sympathovagal Balance in Mice
Becari, C., Durand, M., Guimaraes, A., Lataro, R. M., Prado, C. M., de Oliveira, M., Candido, S. C. O., Pais, P., Ribeiro, M. S., Bäder, M., et al. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00170 · Cited by 14
Effects of Irbesartan Pretreatment on Pancreatic β‐Cell Apoptosis in STZ‐Induced Acute Prediabetic Mice
Chen, C., Li, L., Qin, H., Huang, Z., Xian, J., Cai, J., Qin, Y., Zhang, J., & Liang, X. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/8616194 · Cited by 14
Trandolapril/Verapamil Sustained Release
Reynolds, N. A., Wagstaff, A. J., & Keam, S. J. (2005) · Drugs · doi:10.2165/00003495-200565130-00011 · Cited by 14
Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study
Cho, K. I., Kim, B. H., Park, Y. H., Ahn, J.-C., Kim, S., Chung, W., Kim, W., Sohn, I. S., Shin, J., Kim, Y. J., et al. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.05.007 · Cited by 13
PHYSIOLOGY AND ENDOCRINOLOGY SYMPOSIUM: Insulin action and lipotoxicity in the development of polycystic ovary syndrome: A review1
Faubert, J., Battista, M., & Baillargeon, J. (2016) · Journal of Animal Science · doi:10.2527/jas.2015-0089 · Cited by 12
Clinical Characteristics and Outcomes in Hypertensive Patients of Hispanic Descent
Aranda, J. M., Calderon, R., & Aranda, J. M. (2008) · Preventive Cardiology · doi:10.1111/j.1751-7141.2008.08008.x · Cited by 12
Adipogenic differentiation of adipose tissue-derived human mesenchymal stem cells: effect of gastric bypass surgery
Chen, J.-G., Spagnoli, A., & Torquati, A. (2012) · Surgical Endoscopy · doi:10.1007/s00464-012-2353-x · Cited by 12
Adiposity Gain During Childhood, ACE I/D Polymorphisms and Metabolic Outcomes
Ponsonby, A., Blizzard, L., Pezic, A., Cochrane, J., Ellis, J. A., Morley, R., Dickinson, J. L., Sale, M. M., Richards, S. M., & Dwyer, T. (2008) · Obesity · doi:10.1038/oby.2008.302 · Cited by 12
Valsartan-induced improvement in insulin sensitivity is not paralleled by changes in microvascular function in individuals with impaired glucose metabolism
van der Zijl, N. J., Serné, E. H., Goossens, G. H., Moors, C. C. M., IJzerman, R. G., Blaak, E. E., & Diamant, M. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834a7667 · Cited by 12
Effect of Pregnancy and Diabetes on Vascular Receptors for Angiotensin II
Velazquez-Roman, J. A., Villafaña, S., López‐Sánchez, P., Fernandez-Vallín, E., & Bobadilla-Lugo, R. A. (2011) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2010.531843 · Cited by 11
Pediatric Nephrology for Primary Care
American Academy of Pediatrics (2008) · American Academy of Pediatrics eBooks · doi:10.1542/9781581104356 · Cited by 11
Associations of renin–angiotensin system inhibitor use with brain insulin signaling and neuropathology
Tong, H., Capuano, A. W., Mehta, R. I., Sood, A., Bennett, D. A., Ahima, R. S., Arnold, S. E., & Arvanitakis, Z. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52132 · Cited by 10
Relationship between resistin and aPAI‐1 levels with insulin resistance in Saudi children
Al‐Daghri, N. M., Al-Attas, O. S., Alokail, M. S., Alkharfy, K. M., & Draz, H. M. (2010) · Pediatrics International · doi:10.1111/j.1442-200x.2010.03091.x · Cited by 10
Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome
Althanoon, Z. A., & Mahmood, I. H. (2012) · Oman Medical Journal · doi:10.5001/omj.2012.05 · Cited by 10
Vascular Effects of Avocado Seed Glycosides during Diabetes-induced Endothelial Damage
Amadi, P. U., Agomuo, E. N., & Adumekwe, C. W. (2020) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x20666200510012012 · Cited by 10
Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation
Yamagishi, S., Takenaka, K., & Inoue, H. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2005.07.018 · Cited by 11
Inhalation of Human Insulin (Exubera) Augments the Efficiency of Muscle Glucose Uptake In Vivo
Edgerton, D. S., Cherrington, A. D., Williams, P. J., Neal, D. W., Scott, M. F., Bowen, L. E., Wilson, W., HOBBS, C. H., Leach, C., Kuo, M.-C., et al. (2006) · Diabetes · doi:10.2337/db06-0718 · Cited by 10
Editorial Comment: Secondary Prevention of Stroke Is Important
Strandberg, T. E. (2005) · Stroke · doi:10.1161/01.str.0000166044.06026.46 · Cited by 10
Glucose Metabolism in Outpatients with New-Onset Hypertension in Chinese Han Population
Gu, P., Jiang, W., Cheng, M., Lü, B., Shao, J., Du, H., & Jiang, S. (2012) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2012.666601 · Cited by 9
Disruption of Insulin Receptor Signaling in Endothelial Cells Shows the Central Role of an Intact Islet Blood Flow for In Vivo β-Cell Function
Carlsson, P., & Jansson, L. E. (2015) · Diabetes · doi:10.2337/db14-1523 · Cited by 9
Targeting the renin–angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Kjeldsen, S. E., Lyle, P. A., Tershakovec, A. M., Devereux, R. B., Oparil, S., Dahlöf, B., Fairé, U. D., Fyhrquist, F., Ibsen, H., Kristianson, K. J., et al. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.4.729 · Cited by 9
Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other angiotensin-receptor blockers
Fuenfstueck, R., Hempel, R. D., Ansari, A., Weidinger, G., & Klebs, S. H. G. (2005) · Advances in Therapy · doi:10.1007/bf02849935 · Cited by 9
Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes
Bozkurt, Ö., de Boer, A., Grobbee, D. E., Kroon, A. A., Schiffers, P. M. H., de Leeuw, P. W., & Klungel, O. H. (2009) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320309104877 · Cited by 9
Beneficial effects of ramipril on myocardial diastolic function in patients with type 2 diabetes mellitus, normal LV systolic function and without coronary artery disease: a prospective study using tissue Doppler
Siegmund, T., Schumm‐Draeger, P., Antoni, D., & von Bibra, H. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.065 · Cited by 9
Comparative Study of the Effects of Azilsartan and Telmisartan on Insulin Resistance and Metabolic Biomarkers in Essential Hypertension Associated With Type 2 Diabetes Mellitus
Meher, B. R., Mohanty, R. R., Sahoo, J. P., Jena, M., Srinivasan, A., & Padhy, B. M. (2022) · Cureus · doi:10.7759/cureus.22301 · Cited by 8
Prorenin and secreted frizzled-related protein 4 levels in women with gestational diabetes mellitus
Baldane, S., İpekçi, S. H., Kebapçılar, A., Abusoglu, A., Beyhekim, H., İlhan, T. T., Ünlü, A., & Kebapçılar, A. (2018) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2018_083 · Cited by 8
The efficacy of angiotensin converting enzyme inhibitors versus angiotensin II receptor blockers on insulin resistance in hypertensive patients
Yao, J., Gong, X., Shi, X., Fan, S., Chen, J., & Qiu, C. (2020) · Medicine · doi:10.1097/md.0000000000020674 · Cited by 8
Preserving insulin secretion in Type 2 diabetes mellitus
Tibaldi, J. M. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.2.147 · Cited by 8
Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?
Karagiannis, A. I., Mikhailidis, D. P., Kakafika, A. I., Τζιόμαλος, Κ., & Athyros, V. G. (2006) · Current Pharmaceutical Design · doi:10.2174/138161207779313713 · Cited by 8
Candesartan: widening indications for this angiotensin II receptor blocker?
Mendis, B., & Page, S. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903092197 · Cited by 8
Antihypertensive therapy in the obese hypertensive patient
Chrostowska, M., Szczęch, R., & Narkiewicz, K. (2006) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000242173.14082.dc · Cited by 8
A Guide to the Management of Blood Pressure in the Diabetic Hypertensive Patient
Shammas, N. W., Sica, D. A., & Toth, P. P. (2009) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03256572 · Cited by 8
Inhalation of Human Insulin Is Associated with Improved Insulin Action Compared with Subcutaneous Injection and Endogenous Secretion in Dogs
Edgerton, D. S., Stettler, K. M., Neal, D. W., Scott, M. F., Bowen, L. E., Wilson, W., HOBBS, C. H., Leach, C., Strack, T. R., & Cherrington, A. D. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.108373 · Cited by 8
Angiotensin Receptor Blockers: Novel Role in High-Risk Patients
Javed, U., & DEEDWANIA, P. C. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2008.07.001 · Cited by 7
Metabolic Side Effects and Cardiovascular Events of Diuretics: Should a Diuretic Remain the First Choice Therapy in Hypertension Treatment? The Case of Yes
Papadopoulos, D. P., & Papademetriou, V. (2007) · Clinical and Experimental Hypertension · doi:10.1080/10641960701743964 · Cited by 7
The “Weight” of Obesity on Arterial Hypertension
Noce, A., & Daniele, N. D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.87774 · Cited by 8
Polymorphism of the aldosterone synthase gene is not associated with progression of diabetic nephropathy, but associated with hypertension in type 2 diabetic patients
Ko, G. J., Kang, Y. S., Lee, M., Song, H. K., Kim, H. K., & Cha, D. R. (2008) · Nephrology · doi:10.1111/j.1440-1797.2008.01005.x · Cited by 7
β-Blocking Agents
Opie, L. H., & Horowitz, J. D. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-6158-8.50006-x · Cited by 7

Authors: Jandeleit-Dahm, K. A., Tikellis, C., Reid, C. M., Johnston, C. I., & Cooper, M. E.
Affiliations: Baker Heart and Diabetes Institute (AU)
ORCID: Reid, Christopher M
Cooper, Mark E
Venue: Journal of Hypertension
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2005-03
Volume: 23
Issue: 3
Pages: 463-473
ISSN: 0263-6352 (ISSN-L)
DOI: 10.1097/01.hjh.0000160198.05416.72
OpenAlex: W2048359273
Cited by: 293
References: 89
Citations by year: 2026: 2 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 4 · 2020: 11 · 2019: 7 · 2018: 15 · 2017: 7 · 2016: 3 · 2015: 10 · 2014: 14 · 2013: 8 · 2012: 17
FWCI: 6.04
Type: journal article
Language: en
Open access: closed
Locations: Journal of Hypertension (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords: renin-angiotensin system, ACE inhibitors, angiotensin receptor blockers, type 2 diabetes prevention, new-onset diabetes, insulin resistance, beta-cell death, angiotensin II, hypertension, obesity, antihypertensive drugs, calcium channel blockers, combination antihypertensive therapy
MeSH terms: Angiotensin-Converting Enzyme Inhibitors, Diabetes Mellitus, Type 2, Humans, Hypertension, Renin-Angiotensin System, Incidence, Angiotensin II Type 1 Receptor Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks